The American Diabetes Association Demonstrates Its Commitment to Curbing the Obesity Epidemic with Obesity Standards of Care
illi News/10304318

Trending...
CHICAGO, June 20, 2025 ~ During the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago, the Obesity Association™, a division of the ADA, announced the publication of Weight Stigma and Bias: Standards of Care in Overweight and Obesity—2025. This groundbreaking publication, along with its Introduction & Methodology section in BMJ Open Diabetes Research & Care, marks the first clinical guidance for overweight and obesity.

With approximately 110 million American adults affected by obesity and up to 53% of new cases of type 2 diabetes attributed to obesity each year, there is a pressing need for comprehensive and evidence-based guidelines to inform care. The recent symposium on Standards of Care in Overweight and Obesity 2025 Updates at the ADA's Scientific Sessions highlighted key insights on physician guidelines for weight stigma and bias. These include training for healthcare professionals, creating inclusive clinical environments, person-centered communication, shared decision making, and evidence-based interventions.

More on illi News
In addition to these important updates, researchers also discussed what is next for the clinical guidelines. This includes a potential section on pharmacologic treatment as well as a preview of what will be covered in that section.

The Standards of Care in Overweight and Obesity 2025 Updates symposium was just one of many obesity-related presentations at the ADA's Scientific Sessions. From basic research to clinical studies and implementation science, these presentations showcased groundbreaking developments in obesity treatment and care.

Some notable studies that will be presented at the annual meeting include a Phase 2 study on once-monthly MariTide for treating obesity in people with or without type 2 diabetes; outcomes from the ADJUnct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) trial; results from the BELIEVE study on improving weight loss while preserving lean mass; findings from the PATHWEIGH trial on weight management in primary care; data from a Phase 3 RCT of Orforglipron as monotherapy in drug-naïve type 2 diabetes; and the efficacy and safety of CagriSema in adults with overweight or obesity.

More on illi News
"The ADA's Standards of Care in Diabetes guideline is the gold standard for diabetes care and management," said Dr. Raveendhara Bannuru, the ADA's vice president of medical affairs and lead author of the guidelines. "The new Standards of Care in Overweight and Obesity guidelines stand to yield significant impact and progress in patient care, and this is just the beginning."

As part of their ongoing commitment to combating obesity, the ADA continues to develop new clinical practice guidelines and initiatives to advance the quality of care. Dr. Bannuru and other members of the Professional Practice Committee will present their findings on Standards of Care in Overweight and Obesity 2025 Updates at a symposium on Friday, June 20 from 12:45-1:45 p.m.

With these new developments, it is clear that the ADA is dedicated to improving patient care for those affected by overweight and obesity. The publication of Weight Stigma and Bias: Standards of Care in Overweight and Obesity—2025 marks a significant step towards addressing this pressing issue.
Filed Under: Business
Show All News | Disclaimer | Report Violation

0 Comments

Latest on illi News